🇨🇦 Novo Nordisk forgets to extend Semaglutide patent in Canada

Intentional? Maybe 6 months of increased revenue was worth ignoring

Failing to pay a renewal fee in 2019 seems to have cost Novo Nordisk the Semaglutide patent in Canada 6 months before it was due to lapse.

This is tremendous news for accessibility of GLP1s (Semaglutide in particular), so we dug into what happened and why.